Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Siremadlin with venetoclax and azacitidine in unfit adults with acute myeloid leukemia
MOH_2022-05-30_010716Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- May 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of siremadlin, venetoclax and azacitidine in acute myeloid leukemia (AML) (2 arms), sponsored by Novartis. Primary endpoints: Recommended dose for expansion and Complete remission. Started May 2022; status: active, not recruiting.
02
Drugs
siremadlinvenetoclaxazacitidine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on MOH_2022-05-30_010716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-05-30_010716.